Literature DB >> 7848889

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.

B Lund1, M Ryberg, P M Petersen, H Anderson, N Thatcher, P Dombernowsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7848889     DOI： 10.1093/oxfordjournals.annonc.a059018

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

Review 1.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Gemcitabine in non-small cell lung cancer (NSCLC).

Authors:  C Manegold; P Zatloukal; K Krejcy; J Blatter
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.

Authors:  Lin-run Wang; Jian Liu; Ming-zhu Huang; Nong Xu
Journal:  J Zhejiang Univ Sci B       Date:  2007-05       Impact factor: 3.066

4.  Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Authors:  Lisa A Hammond-Thelin; Melanie B Thomas; Michiko Iwasaki; James L Abbruzzese; Yvonne Lassere; Christina A Meyers; Paulo Hoff; Johann de Bono; Jody Norris; Hitoshi Matsushita; Akira Mita; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

5.  Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.

Authors:  Lin-Run Wang; Ming-Zhu Huang; Nong Xu; Jian-Zhong Shentu; Jian Liu; Jie Cai
Journal:  J Zhejiang Univ Sci B       Date:  2005-05       Impact factor: 3.066

6.  Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.

Authors:  A William Blackstock; Joel E Tepper; Donna Niedwiecki; Donna R Hollis; Robert J Mayer; Margaret A Tempero
Journal:  Int J Gastrointest Cancer       Date:  2003

7.  Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study.

Authors:  A Maraveyas; J Sgouros; S Upadhyay; A-H Abdel-Hamid; M Holmes; M Lind
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

8.  A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer.

Authors:  S-B Tan; D Machin; B-C Tai; K-F Foo; E-H Tan
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

9.  Phase I study of gemcitabine using a once every 2 weeks schedule.

Authors:  J B Vermorken; J P Guastalla; S R Hatty; D E Seitz; B Tanis; C McDaniels; M D Clavel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio.

Authors:  Aron Popovtzer; Daniel Normolle; Francis P Worden; Mark E Prince; Douglas B Chepeha; Gregory T Wolf; Carol R Bradford; Theodore S Lawrence; Avraham Eisbruch
Journal:  Transl Oncol       Date:  2014-08       Impact factor: 4.243
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.